Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer

scientific article published on 29 October 2012

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/IJC.27888
P698PubMed publication ID23034738

P50authorYung-Jue BangQ16180903
Do-Youn OhQ87569618
Tae-You KimQ87569625
Kyung Hun LeeQ87845591
Seung-Yong JeongQ89340434
Sae-Won HanQ91404079
Nam-Yun ChoQ104742774
Jae-Gahb ParkQ117206993
Gyeong Hoon KangQ56613348
Seock-Ah ImQ58821370
P2093author name stringKyu Joo Park
Tae-Yong Kim
Hyun-Jung Lee
Jeong Mo Bae
P2860cites workGlobal cancer statisticsQ22241238
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancerQ24614511
Molecular origins of cancer: Molecular basis of colorectal cancerQ24617331
Microsatellite instability in colorectal cancerQ24627393
Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanismsQ28203690
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerQ29614277
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsQ31014850
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sampleQ33383866
Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival dataQ33631924
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapyQ33986683
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.Q34217637
The chromosomal instability pathway in colon cancerQ34570062
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trialQ34607843
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.Q34777582
DNA methylation predicts recurrence from resected stage III proximal colon cancerQ35051119
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysisQ35790157
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sampleQ35855515
Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancerQ36070164
Molecular classification and correlates in colorectal cancerQ36329300
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysisQ37118308
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.Q37157691
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancerQ37185561
Nationwide cancer incidence in Korea, 2003-2005.Q37376891
Worldwide variations in colorectal cancerQ37629430
The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening statusQ38417609
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancerQ38449001
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapyQ43208381
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatinQ43260542
Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 casesQ43735744
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancerQ44217665
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.Q44919656
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.Q51603737
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectcolorectal cancerQ188874
microsatelliteQ265193
P304page(s)2209-2216
P577publication date2012-10-29
P1433published inInternational Journal of CancerQ332492
P1476titleMethylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer
P478volume132

Reverse relations

cites work (P2860)
Q37100708Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer
Q41390136Analysis of the expression level and methylation of tumor protein p53, phosphatase and tensin homolog and mutS homolog 2 in N-methyl-N-nitrosourea-induced thymic lymphoma in C57BL/6 mice
Q40198390Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Q54297781Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors.
Q55071626Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Q28066004CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia Pathway
Q34177058CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China.
Q50607666CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Q26768471Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review
Q35831602Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX.
Q92479179Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies
Q36893961Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin
Q43572389Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer
Q26851060FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy
Q37695253Future directions for the early detection of colorectal cancer recurrence
Q48259649Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy
Q37708015Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.
Q35761956Molecular markers predictive of chemotherapy response in colorectal cancer
Q26785725Molecular phenotypes of colorectal cancer and potential clinical applications
Q47193672Optimizing prognosis-related key miRNA-target interactions responsible for cancer metastasis
Q64930417P16 Methylation Leads to Paclitaxel Resistance of Advanced Non-Small Cell Lung Cancer.
Q56089175Pathway analysis of genetic variants in folate-mediated one-carbon metabolism-related genes and survival in a prospectively followed cohort of colorectal cancer patients
Q36896188Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
Q34553646Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.
Q43462756Prognostic value of p16 promoter hypermethylation in colorectal cancer: a meta-analysis
Q64070757Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer
Q26751035Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy
Q57801319The hypermethylation of p16 gene exon 1 and exon 2: potential biomarkers for colorectal cancer and are associated with cancer pathological staging
Q38730744The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer
Q39194676p16 Methylation is associated with chemosensitivity to fluorouracil in patients with advanced gastric cancer